

**Philip Home: dualities of interest** (revised end 2017)

My medical views may be influenced by the following:

1. I am a UK citizen
2. I am a salaried employee of Newcastle University. I receive a pension from the UK National Health Service. I am morally indebted to colleagues in both.
3. My academic career is dependent on publication and lecturing success
4. Part of my salary has in the past been paid by the UK National Institute of Health and Clinical Excellence (NICE); I have advised drug regulators in Europe and the UK and have spoken at FDA Advisory Committee hearings. I currently advise the MHRA on research applications in the diabetes technology area, and similarly on safety alerts.
5. For myself, or on behalf of institutions with which I am associated, I accept/have accepted funding for research, advisory, and educational activities from most major global pharmaceutical and diagnostic companies. This includes in the last 5 years: Antriabio, AstraZeneca, Biocon, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Hanmi, Janssen/Johnson & Johnson, Merck (MSD), Novo Nordisk, Roche Diagnostics, Roche Pharma, Sanofi, Skyepharma, Takeda. See page 2.
6. My health is dependent on a heart pacemaker. I use statins and triptans.
7. First degree relatives have, or have had, lymphoma, prostate cancer, and type 1 diabetes
8. I have held positions with the International Diabetes Federation, worked with WHO including as a consultant, a number of diabetes patient associations globally, and am on the editorial boards of a number of diabetes journals.
10. I accept funding from charitable and academic sources for extensive educational activities globally, sometimes being aware of a secondary commercial source of the funding (sources as (5)).
11. I was a board member of one international diabetes charity and remain director of one UK-based diabetes charity.

Neither myself nor my wife hold shares or stock in any health-care related commercial concern.

**Philip Home: commercial dualities of interest** (revised end January 2018)

Current, upcoming, or within last 24 months

**Speaker (includes weblectures):**

Merck (MSD), Janssen; Novo Nordisk, Boehringer Ingelheim, diverse diabetes associations/conference organizers (see full CV, teaching)

**Advisory/consultant:**

Antriabio, AstraZeneca, GlaxoSmithKline, Hanmi, Merck (MSD), Roche Diagnostics, Sanofi

**Research (including publication support and DSMBs):**

GlaxoSmithKline, Janssen, Merck (MSD), Roche Diagnostics, Sanofi

I also advise a number of financial and pharmaceutical consulting organizations on an event by event basis